NCT04015778View on ClinicalTrials.gov

A Two-arm (Phase 2) Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China

PHASE2UnknownINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 8, 2019

Primary Completion Date

August 31, 2020

Study Completion Date

July 31, 2024

Conditions
Non Small Cell Lung Cancer
Interventions
BIOLOGICAL

Nivolumab

240mg Q2W or 360mg Q3W

DRUG

carboplatin

AUC 5, d1 every three weeks

DRUG

nab-paclitaxel

135 mg/m2, d1, 8

Trial Locations (1)

510080

RECRUITING

Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Guangdong Association of Clinical Trials

OTHER